Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 7/20 | 0.41 |
| ▸ | HINT1 | P49773 | 3/20 | 0.33 |
| ▸ | TK1 | P04183 | 1/20 | 0.33 |
| ▸ | ADK | P55263 | 1/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | PNP | P00491 | 1/20 | 0.31 |
| ▸ | NT5E | P21589 | 1/20 | 0.31 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.30 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19049899 | 0.89 | STING1 (0.44) | STING1HINT1ADKTLR7HPGD | |
| SCHEMBL19050067 | 0.87 | STING1 (0.38) | STING1HINT1ADKTLR7HPGD | |
| SCHEMBL19049954 | 0.81 | HINT1 (0.51) | STING1HINT1HPGDNT5EPDE3B | |
| SCHEMBL19049970 | 0.81 | STING1 (0.42) | STING1HINT1HPGD | |
| SCHEMBL19049956 | 0.76 | HINT1 (0.36) | STING1HINT1TLR7HPGDPNP | |
| SCHEMBL12154740 | 0.75 | PNP (0.48) | STING1HINT1TLR7HPGDPNP | |
| SCHEMBL1740074 | 0.75 | PNP (0.48) | STING1HINT1TLR7HPGDPNP | |
| SCHEMBL12300458 | 0.75 | PNP (0.48) | STING1HINT1TLR7HPGDPNP | |
| SCHEMBL12150687 | 0.75 | PNP (0.48) | STING1HINT1TLR7HPGDPNP | |
| SCHEMBL6729951 | 0.75 | PNP (0.48) | STING1HINT1TLR7HPGDPNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170183373-A1 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYERMASE | MERCK SHARP & DOHME CORP. (US) | 2017-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170183373-A1 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYERMASE | POLRMT, DUT, RNASE1 | STING1 503/4885HINT1 620/4885TK1 371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.